Market news

BioCryst Pharmaceuticals (NASDAQ:BCRX) is shifting its strategy toward external innovation as it seeks to expand beyond its ORLADEYO hereditary angioedema, or HAE, franchise, newly appointed Chief Executive Officer Charlie Gayer said at a Morgan Stanley event. Gayer, who became CEO on Jan. 1, said

On August 28, 2026, CNBC reported that BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), now consistently profitable on the strength of its hereditary angioedema drug “Orladeyo,” is looking to acquire more rare disease treatments, according to CEO Charlie Gayer. Gayer, who took the role in January, said the company expects to keep growing profits every year and does […]

BioCryst Pharmaceuticals (BCRX) has drawn fresh attention after recent trading left the share price at US$8.12, with the stock down over the past week and month but modestly higher year to date. Recent trading tells a mixed story for BioCryst Pharmaceuticals, with the share price falling 18.47% over the past week and 16.63% over the past month, yet still showing an 8.27% year to date share price return and a 5.45% one year total shareholder return. This suggests that short term momentum is...

NEW HYDE PARK, N.Y., Sept. 08, 2026 (GLOBE NEWSWIRE) -- CareMed, an independent specialty pharmacy, has been selected as a pharmacy partner by BioCryst Pharmaceuticals for Orladeyo® (berotralstat), a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 2 years and older.1 “The addition of Orladeyo reinforces our long-term commitment to supporting rare and complex disease, highlights the strength of our specialty

RESEARCH TRIANGLE PARK, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Tuesday, September 15, 2026, at 9:15 a.m. ET. The link to the live audio webcast and replay of the presentation may be accessed in the Investors & Media section of BioCryst’s website at www.biocryst.com. About BioCryst Pharmaceuticals BioCryst is a global biote

Here is how BioCryst Pharmaceuticals (BCRX) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.

CEO Gayer told CNBC in an interview that the company is now profitable and plans to use that cash to invest in other rare-disease medicines.

The average of price targets set by Wall Street analysts indicates a potential upside of 108.2% in BioCryst (BCRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Rare disease drug development is getting a boost from new funding models and a growing group of smaller biotech buyers.

— Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to <12 years in Japan — RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) has granted marketing approval for once-daily ORLADEYO® (berotralstat) for prophylactic therapy in pediatric patients with hereditary angioedema (HAE) aged 2 to <12 years. “The approval of ORL

BioCryst Pharmaceuticals (BCRX) is back in focus after raising its full year 2026 revenue outlook, reporting detailed second quarter earnings, and highlighting progress across its hereditary angioedema and rare disease pipeline. See our latest analysis for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' recent guidance upgrade and second quarter earnings are arriving alongside a 7 day share price return of 16.76% and a year to date share price return of 41.20%. However, the 5 year total...

BioCryst Pharmaceuticals stock has put up a 53.0% gain over the past three years, yet the current valuation checks still lean on the inexpensive side for this kind of run. That mix raises the question of whether the recent share price is keeping up with what the broader indicators suggest about value. Over the past three years the share price return of 53.0% points to investors already recognising progress at BioCryst Pharmaceuticals, which can limit how much easy upside is left. Revenue...

Motley Fool Press Release.

The consensus price target hints at a 98.7% upside potential for BioCryst (BCRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Investors need to pay close attention to BCRX stock based on the movements in the options market lately.

BioCryst just turned profitable, its HAE drug Orladeyo is minting cash, and a rival's blockbuster acquisition just put the whole rare-disease sector in play. So which pharma giant has the most to lose by letting someone else snap it up first?

BioCryst Pharmaceuticals Inc (BCRX) reports 45% revenue growth, strong Orladeo performance, and a strategic shift toward external pipeline development.

Moby summary of BioCryst Pharmaceuticals, Inc.'s Q2 2026 earnings call

BioCryst Pharmaceuticals (BCRX) has an average rating of Buy and mean price target of $21.90, accord

BioCryst Pharmaceuticals (NASDAQ:BCRX) reported second-quarter results marked by growth in ORLADEYO revenue, the start of shipments for its pediatric oral-pellet formulation, and completion of enrollment in its pivotal navenibart trial for hereditary angioedema, or HAE. President and CEO Charlie Ga

BioCryst Pharmaceuticals (BCRX) reported Q2 earnings Wednesday of $0.30 per diluted share, up from

BioCryst (BCRX) delivered earnings and revenue surprises of +114.29% and +18.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

— Total net revenue of $218.3 million and ORLADEYO® net revenue of $158.2 million — — Operating profit of $98.5 million and Non-GAAP operating profit of $113.2 million — — Maintained Full Year 2026 ORLADEYO revenue guidance of $625 to $645 million and increased total revenue guidance to $690 million to $715 million — — Began shipping ORLADEYO oral pellets to pediatric patients on August 3 — — Completed enrollment in ALPHA-ORBIT, the ongoing pivotal study of navenibart — RESEARCH TRIANGLE PARK, N

BioCryst raised its full-year 2026 total revenue outlook to $690 million to $715 million, up from its previous estimates of $635 million to $660 million.

RESEARCH TRIANGLE PARK, N.C., July 22, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2026 financial results on Wednesday, August 5, 2026. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocr

Detailed price information for Biocryst Pharma Inc (BCRX-Q) from The Globe and Mail including charting and trades.

RESEARCH TRIANGLE PARK, N.C., July 15, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) (“BioCryst” or the “Company”) today announced the appointment of David W. Jenkins, MA, PhD, to the newly created position of Chief Scientific Officer, effective immediately, reporting to Dr. Sandeep Menon, Chief Research and Development Officer. In this role, Dr. Jenkins will build and lead an efficient research team focused on leveraging external innovation, capabilities and partnership

The consensus price target hints at an 118% upside potential for BioCryst (BCRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

BioCryst Pharmaceuticals stock has delivered a 54.7% return over the past three years, and the latest valuation checks still suggest the shares lean cheap rather than stretched. A 54.7% three year return puts BioCryst in clear recovery territory, which raises the question of how much of the story is already reflected in the price. The shift toward external innovation and partnerships can support expectations for a focused rare disease pipeline, while closing the Birmingham facility and...

BioCryst (BCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

BioCryst Pharmaceuticals (NasdaqGS:BCRX) is ending its internal discovery programs and closing its Birmingham, Alabama facility. The company plans to pivot toward external innovation in rare diseases, focusing on partnered or acquired assets. This corporate shift follows renewed M&A discussion in biotech after a large sector acquisition. BioCryst Pharmaceuticals is best known for treatments targeting rare diseases, an area that continues to attract interest from larger drug companies and...